Show simple item record

dc.contributor.authorMcCormack, William J
dc.contributor.authorParker, Andrew E
dc.contributor.authorO'Neill, Luke A
dc.date.accessioned2012-02-01T10:45:16Z
dc.date.available2012-02-01T10:45:16Z
dc.date.issued2012-02-01T10:45:16Z
dc.identifier.citationArthritis Res Ther. 2009;11(5):243. Epub 2009 Oct 14.en_GB
dc.identifier.issn1478-6362 (Electronic)en_GB
dc.identifier.issn1478-6354 (Linking)en_GB
dc.identifier.pmid19835640en_GB
dc.identifier.doi10.1186/ar2729en_GB
dc.identifier.urihttp://hdl.handle.net/10147/207807
dc.description.abstractThe past 10 years have seen the description of families of receptors that drive proinflammatory cytokine production in infection and tissue injury. Two major classes have been examined in the context of inflammatory joint disease--the Toll-like receptors (TLRs) and NOD-like receptors (NLRs). TLRs such as TLR2 and TLR4 are being implicated in the pathology of rheumatoid arthritis, ankylosing spondylitis, lyme arthritis and osteoarthritis. Nalp3 has been identified as a key NLR for IL-1beta production and has been shown to have a particular role in gout. These findings present new therapeutic opportunities, possibly allowing for the replacement of biologics with small molecule inhibitors.
dc.language.isoengen_GB
dc.subject.meshAnimalsen_GB
dc.subject.meshHumansen_GB
dc.subject.meshNod Signaling Adaptor Proteins/immunology/*metabolismen_GB
dc.subject.meshRheumatic Diseases/immunology/*metabolismen_GB
dc.subject.meshToll-Like Receptors/immunology/*metabolismen_GB
dc.titleToll-like receptors and NOD-like receptors in rheumatic diseases.en_GB
dc.contributor.departmentOPSONA Therapeutics Ltd, Institute of Molecular Medicine, Trinity Centre for, Health Sciences, St James' Hospital, Dublin 8, Ireland. wmccormack@opsona.comen_GB
dc.identifier.journalArthritis research & therapyen_GB
dc.description.provinceLeinster
html.description.abstractThe past 10 years have seen the description of families of receptors that drive proinflammatory cytokine production in infection and tissue injury. Two major classes have been examined in the context of inflammatory joint disease--the Toll-like receptors (TLRs) and NOD-like receptors (NLRs). TLRs such as TLR2 and TLR4 are being implicated in the pathology of rheumatoid arthritis, ankylosing spondylitis, lyme arthritis and osteoarthritis. Nalp3 has been identified as a key NLR for IL-1beta production and has been shown to have a particular role in gout. These findings present new therapeutic opportunities, possibly allowing for the replacement of biologics with small molecule inhibitors.


This item appears in the following Collection(s)

Show simple item record